Evidence map›Paper›PMID 37711550›Full record

ArticleFrontiers in cardiovascular medicine2023

Endothelial activation and fibrotic changes are impeded by laminar flow-induced CHK1-SENP2 activity through mechanisms distinct from endothelial-to-mesenchymal cell transition.

Minh T H Nguyen, Masaki Imanishi, Shengyu Li, Khanh Chau, Priyanka Banerjee, Loka Reddy Velatooru, Kyung Ae Ko, Venkata S K Samanthapudi, Young J Gi, Ling-Ling Lee and 15 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 3 institutions in 2 countries.

Minh T H Nguyen *Center for Cardiovascular Regeneration, Department of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, TX, United States.
Masaki Imanishi *Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Shengyu Li *Center for Cardiovascular Regeneration, Department of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, TX, United States.
Khanh Chau *Center for Cardiovascular Regeneration, Department of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, TX, United States.
Priyanka BanerjeeCenter for Cardiovascular Regeneration, Department of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, TX, United States.
Loka Reddy VelatooruCenter for Cardiovascular Regeneration, Department of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, TX, United States.
Kyung Ae KoDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Venkata S K SamanthapudiDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Young J GiDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Ling-Ling LeeDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Rei J AbeCenter for Cardiovascular Regeneration, Department of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, TX, United States.
Elena McBeathDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Anita DeswalDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Steven H LinDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Nicolas L PalaskasDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Robert DantzerDepartment of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Keigi FujiwaraDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Mae K BorchrdtCenter for Cardiovascular Regeneration, Department of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, TX, United States.
Estefani Berrios TurciosCenter for Cardiovascular Regeneration, Department of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, TX, United States.
Elizabeth A Olmsted-DavisCenter for Cardiovascular Regeneration, Department of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, TX, United States.
Sivareddy KotlaDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
John P CookeCenter for Cardiovascular Regeneration, Department of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, TX, United States.
Guangyu WangCenter for Cardiovascular Regeneration, Department of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, TX, United States.
Jun-Ichi AbeDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Nhat-Tu LeCenter for Cardiovascular Regeneration, Department of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, TX, United States.
The University of Texas MD Anderson Cancer Center · USHouston Methodist · USVietnam Academy of Science and Technology · VN

Funding

Pathological flow-induced endothelial damage and plaque erosionR01HL149303 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ABE, JUN-ICHI, COOKE, JOHN P · 2019 to 2022
$3.2M
Premature aging disorders, metabolites, and atherosclerosisR01HL163857 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Jun-Ichi Abe, JOHN P COOKE · 2023 to 2026
$2.9M
Reversal of Heart Failure: Role of Vascular RecoveryR01HL148338 · NHLBI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI CHEN, KAIFU, COOKE, JOHN P · 2020 to 2023
$2.8M
Determinants of COVID19-induced venous thrombosis and targeted therapy assessed with bioengineered vein-chipR01HL157790 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI CONNOR, JOHN H, COOKE, JOHN P · 2021 to 2024
$2.8M
Mitigating radiation-induced cardiovascular disease by inhibiting premature agingU01AI156921 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ABE, JUN-ICHI · 2020 to 2024
$2.5M
A Novel Role for MAGI1 in regulating non-canonical LATS signaling and atherosclerotic plaque formationR01HL134740 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LE, NHAT-TU · 2017 to 2021
$2.0M
NHLBI NIH HHS R01 HL134740NHLBI NIH HHS R01 HL148338NHLBI NIH HHS R01 HL149303NHLBI NIH HHS R01 HL157790NHLBI NIH HHS R01 HL163857NIAID NIH HHS U01 AI156921
6 · The paper itself

Abstract

Background: The deSUMOylase sentrin-specific isopeptidase 2 (SENP2) plays a crucial role in atheroprotection. However, the phosphorylation of SENP2 at T368 under disturbed flow (D-flow) conditions hinders its nuclear function and promotes endothelial cell (EC) activation. SUMOylation has been implicated in D-flow-induced endothelial-to-mesenchymal transition (endoMT), but the precise role of SENP2 in counteracting this process remains unclear. Method: We developed a phospho-specific SENP2 S344 antibody and generated knock-in (KI) mice with a phospho-site mutation of SENP2 S344A using CRISPR/Cas9 technology. We then investigated the effects of SENP2 S344 phosphorylation under two distinct flow patterns and during hypercholesteremia (HC)-mediated EC activation. Result: Our findings demonstrate that laminar flow (L-flow) induces phosphorylation of SENP2 at S344 through the activation of checkpoint kinase 1 (CHK1), leading to the inhibition of ERK5 and p53 SUMOylation and subsequent suppression of EC activation. We observed a significant increase in lipid-laden lesions in both the aortic arch (under D-flow) and descending aorta (under L-flow) of female hypercholesterolemic SENP2 S344A KI mice. In male hypercholesterolemic SENP2 S344A KI mice, larger lipid-laden lesions were only observed in the aortic arch area, suggesting a weaker HC-mediated atherogenesis in male mice compared to females. Ionizing radiation (IR) reduced CHK1 expression and SENP2 S344 phosphorylation, attenuating the pro-atherosclerotic effects observed in female SENP2 S344A KI mice after bone marrow transplantation (BMT), particularly in L-flow areas. The phospho-site mutation SENP2 S344A upregulates processes associated with EC activation, including inflammation, migration, and proliferation. Additionally, fibrotic changes and up-regulated expression of EC marker genes were observed. Apoptosis was augmented in ECs derived from the lungs of SENP2 S344A KI mice, primarily through the inhibition of ERK5-mediated expression of DNA damage-induced apoptosis suppressor (DDIAS). Summary: In this study, we have revealed a novel mechanism underlying the suppressive effects of L-flow on EC inflammation, migration, proliferation, apoptosis, and fibrotic changes through promoting CHK1-induced SENP2 S344 phosphorylation. The phospho-site mutation SENP2 S344A responds to L-flow through a distinct mechanism, which involves the upregulation of both mesenchymal and EC marker genes.

Indexed as

atherosclerosisCHK1endothelial activationfibrotic changeslaminar flowSENP2SUMOylation

Identifiers

PMID37711550
PMCPMC10499395
OpenAlexW4386309054

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.